EXM — Exmceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EXMceuticals Inc. is a bio-sciences company that is focused on the production of cannabinoid formulations. The Company operates through its geographic segments, which include Canada, Portugal, Uganda and Netherlands. The Company’s subsidiaries include EXMceuticals Inc., EXMceuticals Holdings B.V, EXMceuticals Portugal, LDA and EXMceuticals Portugal II, Unipessoal Lda.
Directors
- Last Annual
- June 30th, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- October 9th, 2008
- Public Since
- January 1st, 1970
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 150,895,066
- Address
- 421 7th Avenue SW, 30th Floor, Null, CALGARY, T2P 4K9
- Web
- https://exmceuticals.com/
- Phone
- +1 5873908541
- Auditors
- Dale Matheson Carr-Hilton LaBonte LLP
Upcoming Events for EXM
Similar to EXM
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Acreage Holdings
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
FAQ
As of Today at 06:08 UTC, shares in Exmceuticals are trading at CA$0.20. This share price information is delayed by 15 minutes.
Shares in Exmceuticals last closed at CA$0.20 and the price had moved by -36.51% over the past 365 days. In terms of relative price strength the Exmceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -39.87% over the past year.
There is no consensus recommendation for this security.
Find out moreExmceuticals does not currently pay a dividend.
Exmceuticals does not currently pay a dividend.
Exmceuticals does not currently pay a dividend.
To buy shares in Exmceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.20, shares in Exmceuticals had a market capitalisation of .
Here are the trading details for Exmceuticals:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: EXM
Based on an overall assessment of its quality, value and momentum Exmceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exmceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -25.31%.
As of the last closing price of CA$0.20, shares in Exmceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Exmceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Exmceuticals' management team is headed by:
- Jonathan Summers - CHM
- Michael Kinley - CFO
- Julie Lemieux - SEC